Switch to:
Also traded in: Germany, Mexico, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.02
SHPG's Cash to Debt is ranked lower than
99% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 59.90 vs. SHPG: 0.02 )
Ranked among companies with meaningful Cash to Debt only.
SHPG' s Cash to Debt Range Over the Past 10 Years
Min: 0.02  Med: 1.35 Max: No Debt
Current: 0.02
Equity to Asset 0.43
SHPG's Equity to Asset is ranked lower than
76% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. SHPG: 0.43 )
Ranked among companies with meaningful Equity to Asset only.
SHPG' s Equity to Asset Range Over the Past 10 Years
Min: 0.28  Med: 0.62 Max: 0.83
Current: 0.43
0.28
0.83
Interest Coverage 2.04
SHPG's Interest Coverage is ranked lower than
96% of the 484 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. SHPG: 2.04 )
Ranked among companies with meaningful Interest Coverage only.
SHPG' s Interest Coverage Range Over the Past 10 Years
Min: 2.04  Med: 27.36 Max: 55.13
Current: 2.04
2.04
55.13
F-Score: 5
Z-Score: 1.19
M-Score: -1.46
WACC vs ROIC
10.02%
3.53%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 8.44
SHPG's Operating margin (%) is ranked higher than
78% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -88.13 vs. SHPG: 8.44 )
Ranked among companies with meaningful Operating margin (%) only.
SHPG' s Operating margin (%) Range Over the Past 10 Years
Min: -56.61  Med: 22.5 Max: 35.13
Current: 8.44
-56.61
35.13
Net-margin (%) 2.93
SHPG's Net-margin (%) is ranked higher than
73% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -75.28 vs. SHPG: 2.93 )
Ranked among companies with meaningful Net-margin (%) only.
SHPG' s Net-margin (%) Range Over the Past 10 Years
Min: -59.59  Med: 16.4 Max: 56.55
Current: 2.93
-59.59
56.55
ROE (%) 1.56
SHPG's ROE (%) is ranked higher than
77% of the 874 Companies
in the Global Biotechnology industry.

( Industry Median: -34.32 vs. SHPG: 1.56 )
Ranked among companies with meaningful ROE (%) only.
SHPG' s ROE (%) Range Over the Past 10 Years
Min: -90.17  Med: 17.69 Max: 49.41
Current: 1.56
-90.17
49.41
ROA (%) 0.68
SHPG's ROA (%) is ranked higher than
78% of the 972 Companies
in the Global Biotechnology industry.

( Industry Median: -30.23 vs. SHPG: 0.68 )
Ranked among companies with meaningful ROA (%) only.
SHPG' s ROA (%) Range Over the Past 10 Years
Min: -37.5  Med: 9.75 Max: 31.57
Current: 0.68
-37.5
31.57
ROC (Joel Greenblatt) (%) 14.83
SHPG's ROC (Joel Greenblatt) (%) is ranked higher than
84% of the 925 Companies
in the Global Biotechnology industry.

( Industry Median: -407.53 vs. SHPG: 14.83 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SHPG' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -396.76  Med: 102.56 Max: 345.74
Current: 14.83
-396.76
345.74
Revenue Growth (3Y)(%) 32.10
SHPG's Revenue Growth (3Y)(%) is ranked higher than
83% of the 480 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. SHPG: 32.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
SHPG' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -0.8  Med: 12.95 Max: 32.1
Current: 32.1
-0.8
32.1
EBITDA Growth (3Y)(%) 19.80
SHPG's EBITDA Growth (3Y)(%) is ranked higher than
71% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. SHPG: 19.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
SHPG' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -1.9  Med: 19.8 Max: 34.1
Current: 19.8
-1.9
34.1
EPS Growth (3Y)(%) -25.60
SHPG's EPS Growth (3Y)(%) is ranked lower than
76% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: -3.10 vs. SHPG: -25.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
SHPG' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -25.6  Med: 30.4 Max: 68.8
Current: -25.6
-25.6
68.8
GuruFocus has detected 5 Warning Signs with Shire PLC $SHPG.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» SHPG's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

SHPG Guru Trades in Q1 2016

David Dreman 154 sh (New)
Lee Ainslie 1,630 sh (New)
First Eagle Investment 47,032 sh (+873.75%)
Steven Cohen 197,200 sh (+70.29%)
Ken Fisher 39,657 sh (+16.80%)
Jim Simons 313,212 sh (+12.62%)
John Paulson 7,071,050 sh (+3.31%)
Murray Stahl 6,000 sh (unchged)
Pioneer Investments 15,699 sh (unchged)
Paul Tudor Jones 80,000 sh (unchged)
John Paulson 58,000 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 82,128 sh (unchged)
Paul Singer Sold Out
Andreas Halvorsen 130,870 sh (-4.61%)
» More
Q2 2016

SHPG Guru Trades in Q2 2016

Tweedy Browne Global Value 6,803 sh (New)
Jeff Auxier 1,712 sh (New)
Mario Gabelli 5,874 sh (New)
Tweedy Browne 42,247 sh (New)
Third Avenue Management 47,840 sh (New)
Keeley Asset Management Corp 17,723 sh (New)
Jeremy Grantham 28,297 sh (New)
Daniel Loeb 950,000 sh (New)
Mairs and Power 182,790 sh (New)
Leon Cooperman 204,100 sh (New)
John Buckingham 19,575 sh (New)
Julian Robertson 120,554 sh (New)
Paul Singer 39,372 sh (New)
Steve Mandel 2,529,148 sh (New)
Andreas Halvorsen 1,162,787 sh (+788.51%)
Pioneer Investments 35,875 sh (+128.52%)
Murray Stahl 8,068 sh (+34.47%)
First Eagle Investment 56,549 sh (+20.24%)
Lee Ainslie 1,920 sh (+17.79%)
Ken Fisher 44,092 sh (+11.18%)
John Paulson 88,000 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 82,128 sh (unchged)
Jim Simons Sold Out
David Dreman 140 sh (-9.09%)
John Paulson 5,194,600 sh (-26.54%)
Steven Cohen 130,100 sh (-34.03%)
» More
Q3 2016

SHPG Guru Trades in Q3 2016

Lee Ainslie 570,907 sh (+29634.74%)
Ken Fisher 166,168 sh (+276.87%)
Leon Cooperman 356,484 sh (+74.66%)
Steven Cohen 224,900 sh (+72.87%)
Third Avenue Management 68,224 sh (+42.61%)
Tweedy Browne Global Value 6,803 sh (unchged)
Kyle Bass 110,000 sh (unchged)
John Paulson 60,000 sh (unchged)
Jeff Auxier 1,712 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 82,128 sh (unchged)
Jeremy Grantham Sold Out
Paul Singer Sold Out
John Buckingham 19,504 sh (-0.36%)
Keeley Asset Management Corp 17,322 sh (-2.26%)
David Dreman 134 sh (-4.29%)
Daniel Loeb 900,000 sh (-5.26%)
First Eagle Investment 53,037 sh (-6.21%)
Murray Stahl 7,267 sh (-9.93%)
John Paulson 4,667,800 sh (-10.14%)
Tweedy Browne 36,304 sh (-14.07%)
Steve Mandel 1,694,675 sh (-32.99%)
Andreas Halvorsen 764,762 sh (-34.23%)
Mairs and Power 119,577 sh (-34.58%)
Julian Robertson 78,154 sh (-35.17%)
Pioneer Investments 15,699 sh (-56.24%)
Mario Gabelli 1,242 sh (-78.86%)
» More
Q4 2016

SHPG Guru Trades in Q4 2016

Scott Black 9,560 sh (New)
Lee Ainslie 1,425,420 sh (+149.68%)
Steven Cohen 410,700 sh (+82.61%)
Leon Cooperman 447,307 sh (+25.48%)
Julian Robertson 95,454 sh (+22.14%)
Andreas Halvorsen 919,604 sh (+20.25%)
Keeley Asset Management Corp 19,886 sh (+14.80%)
Steve Mandel 1,904,306 sh (+12.37%)
John Buckingham 20,722 sh (+6.24%)
Tweedy Browne Global Value 6,803 sh (unchged)
Pioneer Investments 15,699 sh (unchged)
John Paulson 160,000 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 82,128 sh (unchged)
First Eagle Investment Sold Out
Daniel Loeb Sold Out
Mario Gabelli Sold Out
David Dreman Sold Out
Third Avenue Management 67,805 sh (-0.61%)
Tweedy Browne 35,534 sh (-2.12%)
Ken Fisher 151,274 sh (-8.96%)
John Paulson 4,206,100 sh (-9.89%)
Murray Stahl 6,000 sh (-17.43%)
Mairs and Power 24,659 sh (-79.38%)
» More
» Details

Insider Trades

Latest Guru Trades with SHPG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:BIIB, OTCPK:CSLLY, NAS:REGN, NAS:ALXN, OTCPK:ALIOY, NAS:INCY, NAS:VRTX, OTCPK:NONOF, NAS:GILD, NAS:BMRN, OTCPK:GIKLY, NAS:CELG, OTCPK:UCBJY, OTCPK:GMXAY, OTCPK:NVZMY, NAS:TSRO, NAS:SGEN, NAS:ALKS, NAS:JAZZ, NAS:UTHR » details
Traded in other countries:S7E.Germany, SHPG N.Mexico, SHP.UK, SHPGF.USA,
Shire PLC is a specialty biopharmaceutical company that focuses on developing and marketing specialty medicines that address unmet patient needs.

Shire PLC is a biotech company incorporated and registered in Jersey on January 28, 2008. The Company is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of medicines to meet unmet patient needs. Its Products include FIRAZYR, LDX, NATPAR, SHP609, GATTEX, INTUNIV, TYVENSE, VENVANSE, OBIZUR, HEMOFIL, FOZNOL among others. The Company develops products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a franchise in Oncology.

Guru Investment Theses on Shire PLC

Keeley All Cap Value Fund Comments on Shire - Jan 27, 2017

Given the volatile Health Care sector this quarter, the Fund’s position in Shire (NASDAQ:SHPG) was also a leading detractor. Headline risk regarding potential pharmaceutical price controls has impacted the stock. With continued synergies from its acquisition of Baxalta and trading at 11x earnings, we feel the stock remains quite attractive.



From the Keeley All Cap Value Fund fourth quarter 2016 commentary.







Check out Keeley Asset Management Corp latest stock trades

Top Ranked Articles about Shire PLC

Keeley All Cap Value Fund Comments on Shire Guru stock highlight
Given the volatile Health Care sector this quarter, the Fund’s position in Shire (NASDAQ:SHPG) was also a leading detractor. Headline risk regarding potential pharmaceutical price controls has impacted the stock. With continued synergies from its acquisition of Baxalta and trading at 11x earnings, we feel the stock remains quite attractive. Read more...
Third Avenue Value Fund Buys 2 Stocks and Adds to 2 Positions in Q4 Fund reveals its picks earlier than most
Third Avenue Management (Trades, Portfolio), a private investment firm founded by legendary value manager Martin Whitman (Trades, Portfolio), ends its quarter on Oct. 31 and revealed the fourth-quarter trades of its Third Avenue Value Fund in its recent letter. Read more...
Steve Mandel Buys Shire, Axes 6 Positions in 2nd Quarter Guru reports quarterly portfolio
Steve Mandel (Trades, Portfolio), founder of Lone Pine Capital, utilizes a long-short equity strategy to create long-term capital growth. During the second quarter, the fund manager bought Shire PLC (NASDAQ:SHPG), reduced three existing positions and eliminated three stakes. Read more...
Leon Cooperman's Omega Buys Netflix, Citigroup, Shire Investor said this year he was finding many undervalued stocks
Leon Cooperman (Trades, Portfolio)’s much-followed firm Omega Advisors added 25 new stocks from a wide variety of industries in the recent quarter. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 121.38
SHPG's P/E(ttm) is ranked lower than
89% of the 277 Companies
in the Global Biotechnology industry.

( Industry Median: 27.60 vs. SHPG: 121.38 )
Ranked among companies with meaningful P/E(ttm) only.
SHPG' s P/E(ttm) Range Over the Past 10 Years
Min: 12.4  Med: 26.35 Max: 162.3
Current: 121.38
12.4
162.3
Forward P/E 11.19
SHPG's Forward P/E is ranked higher than
81% of the 75 Companies
in the Global Biotechnology industry.

( Industry Median: 19.72 vs. SHPG: 11.19 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 72.46
SHPG's PE(NRI) is ranked lower than
78% of the 251 Companies
in the Global Biotechnology industry.

( Industry Median: 27.87 vs. SHPG: 72.46 )
Ranked among companies with meaningful PE(NRI) only.
SHPG' s PE(NRI) Range Over the Past 10 Years
Min: 12.87  Med: 23.28 Max: 106.93
Current: 72.46
12.87
106.93
Price/Owner Earnings (ttm) 30.01
SHPG's Price/Owner Earnings (ttm) is ranked higher than
50% of the 143 Companies
in the Global Biotechnology industry.

( Industry Median: 29.18 vs. SHPG: 30.01 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
SHPG' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 11.33  Med: 24.33 Max: 72.9
Current: 30.01
11.33
72.9
P/B 1.89
SHPG's P/B is ranked higher than
76% of the 1106 Companies
in the Global Biotechnology industry.

( Industry Median: 3.65 vs. SHPG: 1.89 )
Ranked among companies with meaningful P/B only.
SHPG' s P/B Range Over the Past 10 Years
Min: 1.7  Med: 5.48 Max: 14.19
Current: 1.89
1.7
14.19
P/S 4.50
SHPG's P/S is ranked higher than
73% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: 12.50 vs. SHPG: 4.50 )
Ranked among companies with meaningful P/S only.
SHPG' s P/S Range Over the Past 10 Years
Min: 2.25  Med: 4.65 Max: 9.24
Current: 4.5
2.25
9.24
POCF 19.20
SHPG's POCF is ranked higher than
54% of the 204 Companies
in the Global Biotechnology industry.

( Industry Median: 21.56 vs. SHPG: 19.20 )
Ranked among companies with meaningful POCF only.
SHPG' s POCF Range Over the Past 10 Years
Min: 7.66  Med: 17.16 Max: 27
Current: 19.2
7.66
27
EV-to-EBIT 86.11
SHPG's EV-to-EBIT is ranked lower than
89% of the 284 Companies
in the Global Biotechnology industry.

( Industry Median: 19.01 vs. SHPG: 86.11 )
Ranked among companies with meaningful EV-to-EBIT only.
SHPG' s EV-to-EBIT Range Over the Past 10 Years
Min: -16.1  Med: 16.9 Max: 173.7
Current: 86.11
-16.1
173.7
EV-to-EBITDA 23.20
SHPG's EV-to-EBITDA is ranked lower than
61% of the 307 Companies
in the Global Biotechnology industry.

( Industry Median: 19.22 vs. SHPG: 23.20 )
Ranked among companies with meaningful EV-to-EBITDA only.
SHPG' s EV-to-EBITDA Range Over the Past 10 Years
Min: -19.6  Med: 13.55 Max: 33.2
Current: 23.2
-19.6
33.2
PEG 3.86
SHPG's PEG is ranked lower than
67% of the 98 Companies
in the Global Biotechnology industry.

( Industry Median: 2.11 vs. SHPG: 3.86 )
Ranked among companies with meaningful PEG only.
SHPG' s PEG Range Over the Past 10 Years
Min: 0.47  Med: 1.11 Max: 4.43
Current: 3.86
0.47
4.43
Shiller P/E 58.35
SHPG's Shiller P/E is ranked lower than
53% of the 55 Companies
in the Global Biotechnology industry.

( Industry Median: 47.42 vs. SHPG: 58.35 )
Ranked among companies with meaningful Shiller P/E only.
SHPG' s Shiller P/E Range Over the Past 10 Years
Min: 42.92  Med: 100.32 Max: 469
Current: 58.35
42.92
469
Current Ratio 0.97
SHPG's Current Ratio is ranked lower than
88% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. SHPG: 0.97 )
Ranked among companies with meaningful Current Ratio only.
SHPG' s Current Ratio Range Over the Past 10 Years
Min: 0.61  Med: 1.54 Max: 7.07
Current: 0.97
0.61
7.07
Quick Ratio 0.51
SHPG's Quick Ratio is ranked lower than
91% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: 3.91 vs. SHPG: 0.51 )
Ranked among companies with meaningful Quick Ratio only.
SHPG' s Quick Ratio Range Over the Past 10 Years
Min: 0.44  Med: 1.35 Max: 6.9
Current: 0.51
0.44
6.9
Days Inventory 291.59
SHPG's Days Inventory is ranked lower than
84% of the 439 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. SHPG: 291.59 )
Ranked among companies with meaningful Days Inventory only.
SHPG' s Days Inventory Range Over the Past 10 Years
Min: 126.5  Med: 189.11 Max: 291.59
Current: 291.59
126.5
291.59
Days Sales Outstanding 89.10
SHPG's Days Sales Outstanding is ranked lower than
67% of the 592 Companies
in the Global Biotechnology industry.

( Industry Median: 62.87 vs. SHPG: 89.10 )
Ranked among companies with meaningful Days Sales Outstanding only.
SHPG' s Days Sales Outstanding Range Over the Past 10 Years
Min: 47.71  Med: 69.72 Max: 89.1
Current: 89.1
47.71
89.1

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.44
SHPG's Dividend Yield is ranked lower than
88% of the 222 Companies
in the Global Biotechnology industry.

( Industry Median: 1.23 vs. SHPG: 0.44 )
Ranked among companies with meaningful Dividend Yield only.
SHPG' s Dividend Yield Range Over the Past 10 Years
Min: 0.23  Med: 0.41 Max: 0.7
Current: 0.44
0.23
0.7
Dividend Payout 0.41
SHPG's Dividend Payout is ranked lower than
58% of the 126 Companies
in the Global Biotechnology industry.

( Industry Median: 0.32 vs. SHPG: 0.41 )
Ranked among companies with meaningful Dividend Payout only.
SHPG' s Dividend Payout Range Over the Past 10 Years
Min: 0.04  Med: 0.1 Max: 0.41
Current: 0.41
0.04
0.41
Dividend Growth (3y) 26.40
SHPG's Dividend Growth (3y) is ranked higher than
81% of the 88 Companies
in the Global Biotechnology industry.

( Industry Median: 7.70 vs. SHPG: 26.40 )
Ranked among companies with meaningful Dividend Growth (3y) only.
SHPG' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 15.65 Max: 57.8
Current: 26.4
0
57.8
Forward Dividend Yield 0.44
SHPG's Forward Dividend Yield is ranked lower than
67% of the 212 Companies
in the Global Biotechnology industry.

( Industry Median: 1.38 vs. SHPG: 0.44 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 1.07
SHPG's Yield on cost (5-Year) is ranked lower than
70% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 1.71 vs. SHPG: 1.07 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
SHPG' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.56  Med: 0.99 Max: 1.7
Current: 1.07
0.56
1.7
3-Year Average Share Buyback Ratio -14.80
SHPG's 3-Year Average Share Buyback Ratio is ranked lower than
60% of the 556 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. SHPG: -14.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SHPG' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -50.3  Med: -2.15 Max: 0.4
Current: -14.8
-50.3
0.4

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 2.03
SHPG's Price/Projected FCF is ranked higher than
67% of the 174 Companies
in the Global Biotechnology industry.

( Industry Median: 3.31 vs. SHPG: 2.03 )
Ranked among companies with meaningful Price/Projected FCF only.
SHPG' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.16  Med: 1.96 Max: 2.94
Current: 2.03
1.16
2.94
Price/Median PS Value 0.96
SHPG's Price/Median PS Value is ranked higher than
51% of the 765 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. SHPG: 0.96 )
Ranked among companies with meaningful Price/Median PS Value only.
SHPG' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.67  Med: 1.01 Max: 2.69
Current: 0.96
0.67
2.69
Price/Peter Lynch Fair Value 3.67
SHPG's Price/Peter Lynch Fair Value is ranked lower than
74% of the 72 Companies
in the Global Biotechnology industry.

( Industry Median: 1.56 vs. SHPG: 3.67 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
SHPG' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.64  Med: 1.35 Max: 3.67
Current: 3.67
0.64
3.67
Earnings Yield (Greenblatt) (%) 1.20
SHPG's Earnings Yield (Greenblatt) (%) is ranked higher than
79% of the 1203 Companies
in the Global Biotechnology industry.

( Industry Median: -9.03 vs. SHPG: 1.20 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SHPG' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.6  Med: 5.5 Max: 8.4
Current: 1.2
0.6
8.4
Forward Rate of Return (Yacktman) (%) 20.33
SHPG's Forward Rate of Return (Yacktman) (%) is ranked higher than
57% of the 122 Companies
in the Global Biotechnology industry.

( Industry Median: 15.82 vs. SHPG: 20.33 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
SHPG' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 1.5  Med: 2.4 Max: 28.9
Current: 20.33
1.5
28.9

More Statistics

Revenue (TTM) (Mil) $11,397
EPS (TTM) $ 1.62
Beta1.73
Short Percentage of Float0.31%
52-Week Range $150.06 - 209.22
Shares Outstanding (Mil)301.53

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 15,335 16,689 16,681
EPS ($) 15.83 18.56 19.30
EPS w/o NRI ($) 15.83 18.56 19.30
EPS Growth Rate
(3Y to 5Y Estimate)
12.71%
Dividends Per Share ($) 1.24 1.82
» More Articles for SHPG

Headlines

Articles On GuruFocus.com
Andreas Halvorsen Buys Maker of First-in-Class Cancer Treatments, Calithera Biosciences Feb 22 2017 
Keeley All Cap Value Fund Comments on Shire Jan 27 2017 
KEELEY All Cap Value Fund 4th Quarter Commentary Jan 27 2017 
Third Avenue Value Fund Buys 2 Stocks and Adds to 2 Positions in Q4 Dec 23 2016 
Julian Robertson Sells Delta Air Lines, Alphabet Dec 07 2016 
John Paulson's Largest 3rd Quarter Trades Dec 01 2016 
Momenta Pharmaceuticals Announces Positive Results for Humira Biosimilar Nov 30 2016 
Samuel Isaly Makes 9 New Buys in 3rd Quarter Nov 04 2016 
Martin Whitman's Top Recent Investments Oct 12 2016 
John Paulson’s Health Care Picks Plunge in Flat Year for Sector Oct 06 2016 

More From Other Websites
New England Journal of Medicine Publishes Phase 1b Results for Shire's Investigational Treatment for... Feb 23 2017
Shire Launches 'Rare Count' Campaign to Personalize the Global Impact of Rare Diseases Feb 23 2017
SHIRE PLC Files SEC form 10-K, Annual Report Feb 22 2017
Momenta Tops Q4 Earnings, Shares Down on Warning Letter Feb 22 2017
Shire Plc :SHPG-US: Earnings Analysis: 2016 By the Numbers : February 22, 2017 Feb 22 2017
Momenta 4Q Net 60 Cents a Share Feb 22 2017
SHIRE PLC Files SEC form 8-K, Financial Statements and Exhibits Feb 21 2017
Shire Plc :SHPG-US: Earnings Analysis: Q4, 2016 By the Numbers : February 21, 2017 Feb 21 2017
Shire (SHPG) Beats on Q4 Earnings, Sales; Gives Upbeat View Feb 17 2017
Shire PLC 4Q Earnings, Revenue Beat Street Feb 17 2017
SHIRE PLC Files SEC form 8-K, Financial Statements and Exhibits Feb 17 2017
Drugmaker Shire Tops Q4 Views; Stock Pops To Six-Week High Feb 16 2017
Is this the FTSE 100’s top growth stock? Feb 16 2017
Shire beats Street 4Q forecasts Feb 16 2017
Shire beats Street 4Q forecasts Feb 16 2017
Shire Reports Full Year 2016 Results With Record Revenue; Positioned for Continued Strong Growth... Feb 16 2017
Shire Beats Full-Year Earnings Estimates, Sees Robust 2017 Growth Feb 16 2017
SHIRE PLC Files SEC form 8-K, Financial Statements and Exhibits Feb 15 2017
Amicus Therapeutics Updates Migalastat Drug Feb 15 2017
Shire to Highlight Advancements in Rare Genetic Diseases Feb 14 2017
Shire ViroPharma Sued By FTC Over Sham FDA Filings Feb 08 2017
FTC says Shire unit used illegal tactics to block generic competition Feb 07 2017
Should you buy or sell AstraZeneca plc after FY sales fall 5%? Feb 02 2017
Director Declaration Jan 06 2017
Shire Announces Seventh Annual ... Jan 04 2017
Director Declaration Jan 04 2017
Shire to present at the 35th ... Jan 04 2017
Total Voting Rights Jan 03 2017
Kick-start 2017 with these explosive growth stocks Jan 03 2017
Directorate Change Jan 03 2017
Directorate change Jan 03 2017
Shire announces FDA approval of ... Dec 27 2016
Director/PDMR Shareholding Dec 19 2016
Total Voting Rights Dec 01 2016
Block Listing Six Monthly Return Nov 23 2016
Blocklisting - Interim Review Nov 23 2016
Shire to Establish Rare Disease ... Nov 22 2016
Shire launches CUVITRU™ [Immune ... Nov 16 2016
Tolerability Data for Shire’s ... Nov 12 2016
Shire sees opportunity in Asia, aims to double revenue by 2020 Nov 11 2016
Shire sees opportunity in Asia, aims to double revenue by 2020 Nov 11 2016
Shire sees opportunity in Asia, aims to double revenue by 2020 Nov 11 2016
BROAD RANGE OF RESEARCH TO BE ... Nov 04 2016
Shire to Highlight Focus on Rare ... Nov 04 2016
Second Price Monitoring Extn Nov 01 2016
Shire reports Q3 2016 results with ... Nov 01 2016
3rd Quarter Results Nov 01 2016
Britain's FTSE slips, though posts fifth straight month of gains Oct 31 2016
Shire raises eyebrows with stunning debut Sep 23 2016
HIGHGRADE CLOSE-Five high-grade issuers raise US$15.614bn Sep 19 2016
Shire to roadshow benchmark US dollar bond Sept 12-15: Source Sep 07 2016
Shire to roadshow benchmark US dollar bond Sept 12-15: Source Sep 07 2016
Elliott Associates sues AbbVie over failed bid for Shire Aug 05 2016
Shire lifts earnings and Baxalta cost saving targets Aug 02 2016
Shire on a roll as U.S. approves keenly awaited eye drug Jul 12 2016
Shire CEO to update on Baxalta savings next month Jul 12 2016
FDA approves Shire's keenly-watched eye drug Jul 11 2016
Shire buys bowel drug rights from Pfizer Jun 14 2016
CORRECTING and REPLACING Baxalta Shareholders Vote to Approve Combination May 27 2016
Royal London, Hermes take aim at UK plc pay plans Apr 28 2016
Shire director pay resolution just scrapes though at general meet Apr 28 2016
London open: Stocks slide on fall in oil prices, Brexit fears Feb 24 2016
FTSE 100 movers: Sports Direct slumps on Jefferies note; Coca-Colla rallies Feb 19 2016
London open: FTSE opens flat ahead of UK retail sales, US inflation Feb 19 2016
London midday: Stocks decline as oil prices slide Feb 18 2016
FTSE 100 movers: IAG and Merlin provide lift Feb 16 2016
London open: Stocks edge higher as oil prices rise Feb 16 2016
London close: Stocks rise on higher yuan, analysts' optimism Feb 15 2016
Shire says internal synergy goals from Baxalta deal higher Jan 12 2016
Drugmaker Shire to buy Baxalta for $32 billion after six-month pursuit Jan 11 2016
Drugmaker Shire to buy Baxalta for $32 billion after 6-month pursuit Jan 11 2016
Shire, Baxalta to announce merger as soon as Monday - sources Jan 07 2016
Exclusive - Shire closer to deal to buy Baxalta: sources Dec 22 2015
Exclusive - Shire closer to deal to buy Baxalta: sources Dec 22 2015
Deals of the day- Mergers and acquisitions Nov 02 2015
Videogame maker says study shows its game helps manage ADHD symptoms Oct 28 2015
Shire's eye drug data could strengthen bid for Baxalta, says CEO Oct 27 2015
Actelion raises 2015 earnings forecast after strong drug sales Oct 20 2015
UK shares lag Europe after Zurich drops RSA bid Sep 21 2015
Shire seen having wiggle room on price in $30 billion Baxalta battle Aug 13 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)